A range of bioconjugations, and they're all listed here. Although I said that we don't, we do in vivo, in vitro, so we don't do in vivo. Down the bottom you can see that we can do in vivo. But we focus on in vitro diagnostics and immunoassays, and those listed there. Next slide, please. Really to the nitty-gritty about who we are and what we do. It's pretty important to talking about sales of our product, and that's what we do, chemicals company, sales of AnteoBind NXT. First of all, as you can see, we're talking about tests and end applications for diagnostics that require testing. For their end-specific use, they require testing by our customers. That in itself takes time.
For people to get a sample, to see that it works in their particular application, it's not just something you buy, put in and away you go. That's the first thing to say. There is a testing process to make sure our product fits with what the customer is trying to do. Secondly, there is an aspect around the product life cycle. New products is what we really target. Because if it's an established product, and by that you just could take the example of, for example, a pregnancy test. Now, that has to be registered through the Therapeutic Goods Administration. There's requirements and standards that go into that, for it to be able to be sold in the market. The switching costs are significant.
Of course, we see our product can perform better in certain circumstances, and those benefits may be enough for parties to switch, particularly if they're having difficulties with traditional chemistries. Really where our sweet spot is is in new products. That's why we're doing a lot of work in India, which for most people are working globally in diagnostics. They understand that there's a lot of money in new modern medicine, precision medicine, testing, development, vaccine development, all sorts of things going on in India that's been supported by the Indian government. We really need to be where new products are being developed. That being said, the Life Sciences business unit is in a very positive position.
Over the past six months, the number of evaluations, the number of samples we have out for testing has grown across Europe, North America, India, other parts of Asia. Really, we have streamlined the understanding around who it is that we need to target, streamlined our internal processes around explaining our product and what it can do. Marketing collateral we've put, and in terms of sales, we've been assembling a sales team and also making sure that we're getting to the right people who are the decision-makers around purchases of these sorts of products. We do actually have two white papers that are available on request through our website.
One is on the lateral flow Luminex side of around AnteoBind and how it all works, and the other one we released within the last couple of weeks, which is around our testing of how coated magnetic particles, AnteoBind NXT coated magnetic particles for use in chemiluminescence luminescent diagnostics perform better than some of the traditional chemistries that are used. In addition, we've made it public that we are engaging with some large life sciences companies who are in these spaces, who we have engaged with before, and we're taking a very structured approach to developing those relationships again. We did make an announcement about that. That then brings me to where we see some potential for the company to move forward. To the next slide, please. Let's talk about the chemiluminescence market.
It's a big market, and in terms of what comprises that market, it's really what we're interested in: the consumables, the particles, and if you could, on the right-hand side, really globally at the top part shows what's in our white paper around testing of AnteoBind activated particles, magnetic particles, relative to traditional chemistries that are used in chemiluminescence. Given that we know that we've got a product that can offer us value in the market, we've started to look at the global chemiluminescence market, and it's significant, and we're looking at the consumer side, and particularly the particles. What we're in the early stages of assessing is where there might be an opportunity for us to get into the market with an AnteoTech product, which is activated particles.
We look forward to keeping people up to date there. It's really part of a very specific strategy for us to move up the value chain, if you like, or to put our product into our AnteoBind NXT, into an overall product where we're a more essential, more core ingredient, and in that way, capture value for our shareholders more significantly. Next slide, please. These are who we already work with. As I said, we've significantly grown our pipeline. We look forward to keeping everyone up to date about where we go.
Next slide. Really to make sure that I to wrap this all up, we've got AnteoBind NXT is the life sciences unique crosslinker that we use, that we sell into the market. It's fast. We've got data that clearly shows that it outperforms traditional chemistries. It supports lower costs end-use applications in a range of ways through antibody usage, the requirement for antibody usage, but also minimizes waste. It brings a whole range of workflow benefits. Really critically, in terms of performance, it's more sensitive, more reproducible, more reliable. Then how do we get into the market more? Luminex and lateral flow, of course, we continue to build what we're doing there.
Really in terms of chemiluminescence, we need to be very careful, very structured, and look at how we want to get into that market, whether it's with very large players or, initially on our own and in specific markets where we've got the right support, the right structure, and we can deliver, based on customer demand. In terms of ELISA plates, we're also looking at that. We see. Again, that will involve a technical paper, and we're really looking forward to the works being done. Currently, we're really looking forward to putting our best foot forward there.
I also talked about biosensors, and our involvement in the likes of MOBIUS allows us to be working with parties who are looking at ways of commercializing new developments where AnteoBind can be used, can be an ingredient as well. Overall, the Life Sciences business unit for AnteoTech is in a good position. We are very, very focused on increasing our sales around what we're already doing and where we have shown that we can, there is a value proposition and advantages for our customers in new sub-sectors within the in vitro diagnostic immunoassays market. Yeah, that's basically what we're looking to do and how we're looking to improve the value creation for shareholders. Happy to take questions.
Great. Thank you very much for the presentation, Merrill. Yeah, we'll jump into some questions. Again, just as a reminder to the audience, if you have one you'd like to submit, please do so using the Q&A option within Zoom, and you can type one in there. Merrill, I'll just start off with one. In terms of shareholder register, the makeup of it, can you just give us a bit of a flavor of how that looks?
Yeah, sure. AnteoTech has been around for some time, and we have a very large retail shareholder base who in fact AnteoTech's chemical platform has really come out of the life sciences business, and then there've been other business units created out of that. We do have a very strong and long-term following within the retail market.
Very good. Another question that already came through during your presentation, have you considered cross-selling with other companies who have testing equipment with the idea of promoting each other's products?
Yeah. That is really, it's a really important part of how we are thinking strategically and making sure that we make good decisions. What we're clear on, what we're really clear on in my time as MD is what our core competency is, what it is that we've truly got, and we know that it's around chemicals and materials. Understanding chemical bonding to a molecule to molecule, other chemicals, as well as molecule to surfaces and substrates. It's really how do we not overstretch ourselves in terms of collaborations with people who bring something to the table, and the answer is yes.
We, even as part of what I've talked about with chemiluminescence and particularly ELISA plates, we see a number of partnerships in there, which is with parties who specialize, who have core competencies in other areas. It I think that's absolutely critical for everything we do at AnteoTech, is understanding that we've got something special to bring to the table, but what we wanna do is be leaders in the next generation in terms of cost, performance, but making sure that we are working with parties who are on the same page as that. They want to take the next step forward, and they bring to the table something that we don't have. We have a program which is around strategic partnerships, and it's pretty important component of that is to be really clear on who's bringing what to the table exactly.
What do you see as the most important catalyst over the next six to 12 months?
Yeah.
In terms of things that, from an investor's perspective could, you know, materially change things?
Yeah. Well, we have started doing work with a very large life sciences company. We've been public about that. We've got milestones that we need to meet in terms of the development work there, and so we are very much looking forward to being able to make statements about meeting those milestones and moving forward. That work is in progress, so we will of course keep the market updated as and when. As I've already said, the board has requested the team to provide options and opportunities around how we may be able to move into different markets, so a pilot market on chemiluminescence and we're working all of that through in terms of detailed analysis and evaluations.
I think most importantly, we have had since June last year a significant focus on increasing sales. What I've clearly stated here is you've gotta be in the right place at the right time, and make sure you have a significant pipeline that allows you to be really in a structured fashion moving through into sales contracts. Now, from my perspective, a great deal of work has been put into that, in making sure we have a much bigger, much more progressive pipeline that will deliver those sorts of sales outcomes. You know, I've already explained which is around the issues around getting in front of the right people and switching costs and are we in the right markets.
We've put a lot of effort into our CRM, which is starting to come to fruition, and our sales team, and making sure that the technical people that we have, the excellent technical team that we have, is supported by professional sales and marketing people. We're using new channels to reach out to customers. We're just really pushing. That's the answer to your question. What do we see? We want to see the sales that we know our product can achieve come to fruition.
Another question that's come through, which I think is interesting and might be alluding to your comment about the biotech company you're working with. The question was simply, why so much secrecy about who AnteoTech is dealing with? I mean, I know from some of the companies I've worked with, I've encountered similar things, but if you just wanna elaborate on that.
I would like to elaborate on that because there just has been in the past some situations. It's not just an AnteoTech one, where perhaps the information about who is being worked with has preceded some of the commercials around exactly what that relationship will mean. The secrecy is. It's not so much secrecy, it's like taking a methodical approach to the value delivery that we expect from any relationship. I think the real key is we just don't wanna get ahead of ourselves here. We're very optimistic. There's no doubt in my mind across the team, we're very optimistic about where things are gonna go, but we need to be measured in that optimism and be able to be clear on what it is that we are going to deliver by when.
It is a really important part of the culture for AnteoTech is to make sure that we're doing everything meticulously, and we're able to disclose when we actually have material contracts behind that. It's very important for us.
Well, thanks very much for your time today, Merrill, and thanks to everyone in the audience. Obviously, if there's any more questions, Merrill's email address is there and readily available, but, thanks for joining us.
Thank you very much for having me. Thank you.
Next up as part of the conference, we have InteliCare, which will take place in about five minutes. Thank you.